AOD-9604
Anti-Obesity Drug 9604
Evolved fat-loss peptide, TGA-recognized safe
How it works
AOD-9604 stimulates fat breakdown and inhibits lipogenesis (fat creation) by mimicking the lipolytic activity of GH without interacting with the GH receptor. It activates beta-3 adrenergic receptors to enhance basal metabolic rate.
What the research explores
In published research, AOD-9604 has been studied in connection with the following. These describe findings reported in the literature — not approved uses, claims, or outcomes to expect.
- Stimulates lipolysis without metabolic side effects
- Inhibits lipogenesis (preventing new fat synthesis)
- Potential cartilage and bone regeneration properties
- Does not affect blood glucose or insulin
- Well-tolerated in Phase IIb clinical trials
- Synergistic with other peptides for recomposition
AOD-9604 holds Generally Recognized as Safe (GRAS) status with the US FDA for use as a food additive, and has completed Phase IIb trials with favorable safety outcomes.
Adverse events & gaps
One of the most comprehensively safety-tested research peptides. No significant adverse events in trials.
Stay Informed on
Peptide Research
Research summaries, newly documented peptides, and clinical trial updates delivered to your inbox.
No spam. Unsubscribe at any time.